ASLNASLAN Pharmaceuticals Ltd

Nasdaq www.aslanpharma.com


$ 0.41 $ 0.00 (-0.24 %)    

Monday, 13-May-2024 12:35:42 EDT
QQQ $ 443.03 $ -0.38 (-0.09 %)
DIA $ 394.52 $ -1.86 (-0.47 %)
SPY $ 520.77 $ -1.82 (-0.35 %)
TLT $ 90.36 $ 0.04 (0.04 %)
GLD $ 216.28 $ -0.90 (-0.41 %)
$ 0.411
$ 0.40
$ 0.39 x 200
$ 0.41 x 100
$ 0.40 - $ 0.41
$ 0.39 - $ 4.69
162,240
na
50.19M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-announces-expansion-of-its-collaboration-with-zenyaku-to-investigate-the-biology-underlying-differential-effects-of-eblasakimab-compared-to-other-biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies ...

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-reports-interim-results-from-phase-2-study-of-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients

https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm 

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 hc-wainwright--co-maintains-buy-on-aslan-pharma-lowers-price-target-to-9

HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...

 piper-sandler-reiterates-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...

 piper-sandler-maintains-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fro...

 piper-sandler-maintains-overweight-on-aslan-pharma-maintains-15-price-target

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and maintains $15 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION